MVAC (Bladder Cancer) - Analysis and Forecasts to 2020


#28411

22pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, MVAC (Bladder Cancer) Analysis and Forecasts to 2020 provides MVAC global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of MVAC including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of MVAC including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2002-2020 for MVAC

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 7

3 Bladder Cancer Disease: Market Characterization 8
3.1 Bladder Cancer Disease Market 8
3.2 Bladder Cancer Disease Market Forecasts and CAGR 8
3.3 Drivers for the Bladder Cancer Disease Market 8
3.3.1 High Prevalence 9
3.3.2 High Incidence 9
3.3.3 High Survival Rate 10
3.3.4 High lifetime costs 10

4 TNM Classification of bladder cancer 11
4.1 American Urological Association 11

5 MVAC 14
5.1 Introduction 14
5.2 Mechanism of Action 14
5.3 Clinical Studies 14
5.4 Approval History of MVAC 15
5.5 Gold Standard Treatment 15
5.6 Sales drivers 16
5.6.1 Bladder Cancer Market 16
5.6.2 Large Unmet need 16
5.6.3 Low Competition 16
3.2.1 Gold Standard Treatment 16
5.7 Drug Evaluation 16
5.8 Sales forecast 17
5.8.1 Target patient Pool of MVAC 17
5.8.2 Dosing 18
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of MVAC 20

6 Bladder Cancer Market: Appendix 21
6.1 Market Definitions 21
6.2 List of Abberiviations 21
6.3 Research Methodology 21
6.3.1 Coverage 21
6.3.2 Secondary Research 21
6.3.3 Forecasting 21
6.3.4 Number of Patients Approved to take the Drug 22
6.3.5 Net Penetration of Drug 22
6.3.6 Net Annual Dosing 22
6.3.7 Annual Cost of Therapy 22
6.3.8 Primary Research 22
6.3.9 Expert Panels 22
6.4 Contact Us 22
6.5 Disclaimer 22
6.6 Sources 22

 


Table 1: Bladder Cancer Incidences & Mortality 5
Table 2: Bladder Cancer, Global, Market Forecast ($bn), 20092020 8
Table 3: Drug Risk Benefit Score of MVAC 17
Table 4: Annual Cost of Therapy 19


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 6
Figure 5: Smoking Consumption Curve, US 6
Figure 6: Bladder Cancer Global Market Forecasted ($bn) 2009-2020 8
Figure 7: All Cancer Incidence Worldwide 9
Figure 8: Bladder Cancer Incidence Worldwide 9
Figure 9: Broad Classification of Bladder Cancer 11
Figure 10: Classification of NMI Bladder Cancer 11
Figure 11: Detailed TNM Classifications 12
Figure 12: Classification of NMI Bladder Cancer 13
Figure 13: Phase III Results, MVAC 15
Figure 14: Drug Model Diagram of MVAC 18
Figure 15: Global Forecast Sales of MVAC ($m) 2002-2020 20
Figure 16: Distribution of MVAC Sales in Major Countries, 2010 21